Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug del… Read More
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has granted a new global, exclusive license to SulfoSyn Limited; the license is for the exclusive glo… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s Dehy… Read More
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its intention to launch new human and animal studies to examine DehydraTECH(TM)-proce… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceut… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For… Read More
The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year
95% of Americans with diabetes are diagnosed wi… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed c… Read More
Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives
The study, which… Read More
Mit DehydraTECH verarbeitete GLP-1-Arzneimittel werden im Hinblick auf folgende potenzielle Verbesserungen bewertet:
– weniger Nebenwirkungen;
– höherer Gewichtsverlust;
&n… Read More
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today reported its intention to conduct a human clinical study to examine DehydraTECH-CBD for purpose… Read More
Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats… Read More
Lexaria is a global innovator in drug delivery platforms with an expanding portfolio of patents that currently stands at 34 granted patents and many patents pending worldwide
These… Read More
Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update
Of note was the company&rsquo… Read More
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraT… Read More
Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD
Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same… Read More
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the… Read More
Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study… Read More
Lexaria held its virtual 2023 Annual Shareholders meeting on May 9, 2023
On the agenda were the election of six director nominees, the ratification of the appointment of the company… Read More
Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1… Read More
Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms
The report discusses the company’s ongoing research and de… Read More
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has received notifications of four new patents either awarded or allowed. In… Read More
Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology
The company has undertaken multip… Read More